Journal
BRITISH JOURNAL OF CANCER
Volume 118, Issue 6, Pages 831-838Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2017.460
Keywords
germ-cell tumours; systemic immune-inflammation index; PD-L1; prognostic factor; immunity
Categories
Funding
- Slovak Research and Development Agency [APVV-15-0086]
Ask authors/readers for more resources
Background: We evaluated systemic immune-inflammation index (SII) and its association with patient outcome in germ-cell tumours (GCTs). Methods: Two independent cohorts of patients were analysed; the discovery set (n = 171) from a single institution and the validation set (n = 181) previously included in a study evaluating PD-L1 in GCTs. The SII was calculated using platelet (P), neutrophil (N) and lymphocyte (L) counts before chemotherapy and correlated with survival using regression analyses and Kaplan-Meier method. Results: In the discovery cohort, the SII was associated with poor risk clinical features. Patients with low SII had significantly longer progression-free survival (HR = 0.22, 95% CI 0.12-0.41, P<0.001) and overall survival (OS) (HR = 0.16, 95% CI 0.08-0.32, P<0.001) compared to high SII. This index was independent of International Germ Cell Cancer Collaborative Group criteria in multivariable Cox regression analysis for OS and was validated in an independent cohort. When combining PD-L1 expression on tumour infiltrating lymphocytes (TILs) and SII, we identified three distinctive prognostic groups. Conclusions: High SII was associated with poor outcome in GCTs. Combination of PD-L1 positive TILs and SII could further refine prognosis in GCTs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available